**Drug Utilization Review (DUR) Meeting Minutes**
**June 2, 2008**

**Members Present:** Patricia Churchill, Cheryl Huber, Norman Byers, Carrie Sorenson, Greg Pfister, Bob Treitline, Kim Krohn, Jeffrey Hostetter, John Savageau, Scott Setzepfandt, and Leeann Ness.
**Medicaid Pharmacy Department:** Brendan Joyce, Gary Betting
**HID Staff Present:** Candace Rieth
**Members Absent:** Carlotta McCleary and Todd Twogood

Chairman, C. Huber, called the meeting to order at 1:00pm. C. Huber asked for a motion to approve the minutes from the April meeting. K. Krohn moved that the minutes be approved and B. Treitline seconded the motion. Chair, C. Huber, called for a voice vote to approve the minutes, which passed with no audible dissent.

**Budget Update**
B. Joyce had no new information to present regarding the budget.

**Anticonvulsant Review**
The board requested additional information at the April meeting regarding anticonvulsants. This information included which agents are going generic in the future, providers prescribing this class of medications, and examples of changes that have been made in other states. B. Joyce reviewed this information with the Board. There was no public comment. B. Joyce explained to the Board that if no recommendation is made regarding anticonvulsants, the Department will recommend to the legislature that the law does not need to exist. C. Huber spoke on behalf of the Board by stating that the Board has no recommendation at this time, related to the class of anticonvulsants.

**Summary of Board Recommendations to Legislative Counsel**
Previous board recommendations on HIV/AIDS, Oncology, ADHD, Antidepressants, and Antipsychotics were reviewed. G. Pfister asked for clarification of the wording on the Antidepressant recommendation. The correct wording will be: Antidepressants-DUR Board recommended placing **certain** SSRI medications on prior authorization and therefore removing the exemption for the antidepressant class of medications.

**Review of Chantix**
Biron Baker, MD, spoke on behalf of Pfizer. He recommended against placing Chantix on prior authorization. Rick Melbye spoke on behalf of Pfizer, manufacturer of Chantix. Michelle Walker spoke on behalf of the North Dakota Department of Health. Michelle is the cessation director and facilitates the North Dakota Tobacco Quitline. B. Joyce stated that the Department would consider covering Chantix for recipients willing to enroll in the Quitline. J. Hostetter made a motion requesting the Department formulate a smoking cessation plan that would cover all smoking cessation products for recipients enrolled in the ND Tobacco Quitline. C. Huber seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

**Review of Soma 250**
B. Joyce reviewed carisoprodol utilization with Board members. There was no public comment. Soma 250mg is a new to market strength of carisoprodol that currently has no generic alternative. N. Byers made a motion to prior authorize Soma 250mg. P. Churchill seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

B. Joyce stated that carisoprodol is indicated for short term use and the Department would like to restrict chronic use of this agent. The Board asked that more information be presented at the September meeting, including tapering information, quantity for scripts, and age/gender for

patients. G. Pfister made a motion that all new prescriptions for carisoprodol be limited to 3 weeks supply with one refill per year. B. Treitline seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

**Yearly PA Review**
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Sedative/Hypnotics, Qualaquin, ACE-Is, and Synagis were reviewed. P. MacDonald spoke on behalf of MedImmune, manufacturer of Synagis. K. Brown, MD, spoke regarding Synagis utilization at St. Alexius. The board recommended that Altace generic be included on the ACE-I form as an available generic. No other changes were made to the forms and criteria for these agents.

**Criteria Recommendations**
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. R. Treitline moved to approve the new criteria and G. Pfister seconded the motion. C. Huber called for a voice vote and the motion passed with no audible dissent.

**Board Member Resignation**
B. Treitline submitted a letter of resignation effective July 1, 2008.

**Election of Chair and Vice-Chair**
B. Treitline made a motion that Carrie Sorenson be considered as the new Chair of the DUR Board. G. Pfister seconded the motion. Chair, C. Huber called for a voice vote with no audible dissent. C. Huber made a motion that J. Hostetter be considered as the new Vice-Chair of the DUR Board. K. Krohn seconded the motion. Chair, C. Huber called for a voice vote with no audible dissent. C. Sorenson and J. Hostetter will serve as the new Chair and Vice-Chair, respectively.

**Board Member Honorarium**
A motion was made by C. Huber to increase the DUR Board member honorarium to one hundred dollars per meeting. B. Treitline seconded the motion. Chair, C. Huber called for a voice vote with no audible dissent.

The next DUR board meeting will be held September 8, 2008. C. Huber made a motion to adjourn the meeting and R. Treitline seconded. Chair C. Huber adjourned the meeting at 3:40 pm.